1-8 of 8
Jennifer A. Woyach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3065–3073.
https://doi.org/10.1158/1078-0432.CCR-22-3887
Published: 15 August 2023
View article titled, B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Open the PDF for B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy in another window
Includes: Supplementary data
Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Daniel Canfield, Casey B. Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A. Rogers, Seema Bhat, Samantha M. Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3242–3247.
https://doi.org/10.1158/1078-0432.CCR-21-3867
Published: 02 August 2022
View article titled, Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Open the PDF for Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 603–608.
https://doi.org/10.1158/1078-0432.CCR-21-1237
Published: 15 February 2022
View article titled, Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Open the PDF for Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare) in another window
Journal Articles

Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, Lindsey Rike, Xiaokui Mo, Mohamed Badawi, Darlene M. Bystry, Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey Jones, Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6187–6195.
https://doi.org/10.1158/1078-0432.CCR-20-1280
Published: 01 December 2020
View article titled, Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
Open the PDF for Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

Fabienne Lucas, Kerry A. Rogers, Bonnie K. Harrington, Alexander Pan, Lianbo Yu, Justin Breitbach, Ralf Bundschuh, Virginia M. Goettl, Zachary A. Hing, Parviz Kanga, Rose Mantel, Deepa Sampath, Lisa L. Smith, Ronni Wasmuth, Danielle K. White, Pearlly Yan, John C. Byrd, Rosa Lapalombella, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6260–6273.
https://doi.org/10.1158/1078-0432.CCR-19-0273
Published: 15 October 2019
View article titled, Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Open the PDF for Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2831–2841.
https://doi.org/10.1158/1078-0432.CCR-16-0463
Published: 31 May 2017
View article titled, The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Open the PDF for The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Fabiola Cervantes-Gomez, Betty Lamothe, Jennifer A. Woyach, William G. Wierda, Michael J. Keating, Kumudha Balakrishnan, Varsha Gandhi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3705–3715.
https://doi.org/10.1158/1078-0432.CCR-14-2809
Published: 13 August 2015
View article titled, Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Open the PDF for Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Sneha V. Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, David M. Lucas
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2406–2419.
https://doi.org/10.1158/1078-0432.CCR-12-2754
Published: 30 April 2013
View article titled, The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
Open the PDF for The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells in another window
Includes: Supplementary data